Thursday 16 October, 2025
Introduction: Compound A is highly soluble at physiological pH, highly bound to proteins (%PPB >99.9%) and has poor permeability (Caco-2…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
Relative impact of CYP2D6 phenotype, physiological changes and hepatic extraction ratio on drug exposure during pregnancy
Thursday 16 October, 2025
Title: Relative impact of CYP2D6 phenotype, physiological changes and hepatic extraction ratio on drug exposure during pregnancy Author: Karen Rowland Yeo1,…
Read moreA Minimal PBPK Model to Predict Biodistribution of Silica Nanoparticles in Mice
Thursday 16 October, 2025
Introduction: Due to their superior drug loading capacity, mechanical stability, and stimuli-responsive release profile for controlled drug delivery, silica nanoparticles…
Read moreSmall molecule drug absorption in inflammatory bowel disease and current implementation in PBPK models.
Thursday 16 October, 2025
Introduction: Inflammatory bowel disease (IBD) is characterized by a chronic inflammation of the intestinal mucosa, with predominant localization in the colon…
Read morePhysiologically based pharmacokinetic modeling and simulation of a promising novel antiplatelet drug vicagrel and its metabolites
Thursday 16 October, 2025
Introduction: Vicagrel, an innovative antiplatelet medication originating from Jiangsu Vcare PharmaTech Co. Ltd., China, is aimed at addressing clopidogrel resistance…
Read moreModelling the whole-body pharmacokinetics (WBPK) of radiolabeled glyburide in healthy volunteers
Thursday 16 October, 2025
Introduction Microdosing approaches allow the administration of infra-therapeutic doses of drug candidates to humans. This approach, carried out upstream of…
Read morePhysiologically-Based Pharmacokinetic Modeling of Extended-Release MK-2048 Formulations for HIV Pre-Exposure Prophylaxis in Non-Human Primates
Thursday 16 October, 2025
Objectives: Human immunodeficiency virus (HIV) remains a significant global health challenge that disproportionately affects young women in sub-Saharan Africa [1]….
Read moreA PBPK model of 4β-hydroxycholesterol, an endogenous biomarker for hepatic CYP3A activity.
Thursday 16 October, 2025
Introduction: New drug candidates are tested for CYP3A enzyme induction in vivo using specific probe substrates. However, due to the cost…
Read morePhysiologically Based Pharmacokinetic modelling of the Drug-Drug Interaction between Ivacaftor and Lefamulin in Cystic Fibrosis patients
Thursday 16 October, 2025
Physiologically-based pharmacokinetic (PBPK) modeling of the combination of ivacaftor and lefamulin in Cystic Fibrosis patients Wolfgang W. Wicha1, Magali…
Read morePhysiologically based pharmacokinetic modelling to predict the concentration-time profile of an antibody-drug conjugate and hepatic and renal impairment.
Thursday 16 October, 2025
Introduction: Antibody-drug conjugates (ADC) present a promising treatment option in oncology. Antibodies have high specificity for their cognate antigens and…
Read more